Eigen Therapeutics

Eigen Therapeutics is a biotechnology company that is dedicated to developing innovative therapies to combat cancer. They focus on the development of priming therapies, which enhance the effectiveness of targeted therapies by addressing cancer heterogeneity. This approach makes cancer cells more vulnerable and healthy cells more resilient to treatment.

Eigen Therapeutics has recently emerged from stealth mode with $7M in funding, demonstrating their commitment to advancing cancer treatment. They aim to revolutionize the field by using their platform to design combination therapies that specifically target tumor heterogeneity. While targeted therapies like CAR T-cell therapies and antibody-drug conjugates have shown great efficacy against cancer cells expressing a specific target, Eigen recognizes that not all cancers have uniform target levels.

By modulating the expression of cancer cell targets, Eigen's co-therapies help targeted therapies hit their mark. This approach reduces side effects and improves outcomes for a wider range of patients. Eigen is building a platform that utilizes machine learning and automation to improve existing targeted therapies, develop combination therapies, and make them accessible for various types of cancers.

Their biology-focused approach includes high-throughput and high-speed combinatorial screening to determine drug therapeutic window. It also involves a complex phenotypic screening workflow to create realistic in vitro models. Eigen leverages robotic workcells and custom-developed lab operations software to streamline and expedite the identification of promising therapies.

They also utilize sophisticated machine learning models and maintain the world's largest heterogeneity atlas to guide co-therapy discovery. Eigen Therapeutics is committed to addressing the unique and complex nature of individual cancers, ultimately improving treatment options and outcomes for cancer patients